{
  "abstract": "We herein report four patients who were unable to receive idecabtagene vicleucel (ide-cel) due to disease progression, despite undergoing leukapheresis within specification. The median age of the patients was 70 (range, 68-77) years old. Two patients had nonsecretory subtypes at the diagnosis. The median number of prior therapy lines was 4.5 (range, 4-6), and 3 patients were penta-refractory. All patients were refractory to the latest treatment. The median time from apheresis to ide-cel cancellation was 44.5 (range: 24-71) days. Our findings suggest that the nonsecretory subtype and penta-refractoriness may increase the risk of treatment discontinuation. Early ide-cel application and improved bridging therapy are warranted to enhance treatment completion after leukapheresis.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 17,
  "authors": [
    {
      "name": "Yoko Nakanishi"
    },
    {
      "name": "Masaki Ri"
    },
    {
      "name": "Shiori Mizutani"
    },
    {
      "name": "Nozomi Nishitarumizu"
    },
    {
      "name": "Yuki Furukawa"
    },
    {
      "name": "Yukiyasu Kato"
    },
    {
      "name": "Hirokazu Sasaki"
    },
    {
      "name": "Arisa Asano"
    },
    {
      "name": "Shiori Kinoshita"
    },
    {
      "name": "Tomotaka Suzuki"
    },
    {
      "name": "Tomoko Narita"
    },
    {
      "name": "Shohei Mizuno"
    },
    {
      "name": "Hiroyuki Miyashita"
    },
    {
      "name": "Takaomi Sanda"
    },
    {
      "name": "Takanori Nanri"
    },
    {
      "name": "Hirokazu Komatsu"
    },
    {
      "name": "Shinsuke Iida"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ctv9s56ag9ag3.bib",
  "cited_by": 0,
  "doi": "10.2169/internalmedicine.6289-25",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6289-25/_article",
  "id": "ctv9s56ag9ag3",
  "issns": [
    "1349-7235",
    "0918-2918"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6289-25/_article",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/general"
    ],
    [
      "openalex",
      "2720|Multiple Myeloma Research and Treatments"
    ]
  ],
  "openalex": "W7117998288",
  "pdf_url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_6289-25/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-08-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/ctv9s56ag9ag3.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:31Z",
      "native_id": "10.2169/internalmedicine.6289-25",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6289-25/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2720|Multiple Myeloma Research and Treatments",
      "subfield": "general"
    }
  ],
  "title": "An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression",
  "title_text": "An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:31Z",
  "url": "https://research.draconitic.com/paper/ctv9s56ag9ag3",
  "venue": "Internal Medicine",
  "versions": []
}